Skip to main content

Dupixent (Dupilumab) Utilization Patterns: A Descriptive Analysis

    Basic Details
    Date Posted
    Monday, July 10, 2023
    Status
    Complete
    Medical Product
    dupilumab dupixent
    Description

    In this request, we investigated utilization patterns of Dupixent (dupilumab). The assessed cohorts differed by inclusion requirement: no inclusion requirement; a diagnosis of eosinophilic esophagitis (EoE) using a narrow definition; a diagnosis of EoE using a broad definition; a diagnosis of other health outcomes including atopic dermatitis, asthma, or chronic rhinosinusitis with nasal polyps; a diagnosis of EoE using the narrow definition and a diagnosis of one of the aforementioned other health outcomes; and a diagnosis of EoE using the broad definition and a diagnosis of one of the aforementioned other health outcomes.

    The study period includes data from January 1, 2017 to March 31, 2020.

    We executed this request on Merative™ MarketScan® Research Databases on July 23, 2021.

    Additional Details
    FDA Center
    CDER
    Time Period
    January 1, 2017 – March 31, 2020
    Study Type
    Query Builder
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    All individuals
    Data Sources
    Merative™ MarketScan® Research Databases